These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26149785)

  • 1. Trends in the development of oral anticoagulants.
    Ralay-Ranaivo B; Borgel D; Couvreur P; Gref R
    Ther Deliv; 2015; 6(6):685-703. PubMed ID: 26149785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
    Petitou M; van Boeckel CA
    Angew Chem Int Ed Engl; 2004 Jun; 43(24):3118-33. PubMed ID: 15199558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
    Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
    Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current issues in anticoagulation.
    Agnelli G
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():2-9. PubMed ID: 15812198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New anticoagulants for treatment of venous thromboembolism.
    Weitz JI
    Circulation; 2004 Aug; 110(9 Suppl 1):I19-26. PubMed ID: 15339877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues.
    Zhou Z; Zhang L; Wu X; Luo L; Wu J; Xu D; Wu M
    Eur J Med Chem; 2022 Apr; 234():114256. PubMed ID: 35279609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice.
    Kalaska B; Kaminski K; Miklosz J; Yusa SI; Sokolowska E; Blazejczyk A; Wietrzyk J; Kasacka I; Szczubialka K; Pawlak D; Nowakowska M; Mogielnicki A
    Transl Res; 2016 Nov; 177():98-112.e10. PubMed ID: 27456749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short- and long-acting synthetic pentasaccharides as antithrombotic agents.
    Walenga JM; Jeske WP; Fareed J
    Expert Opin Investig Drugs; 2005 Jul; 14(7):847-58. PubMed ID: 16022574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin-coated colloidal mesoporous silica nanoparticles efficiently bind to antithrombin as an anticoagulant drug-delivery system.
    Argyo C; Cauda V; Engelke H; Rädler J; Bein G; Bein T
    Chemistry; 2012 Jan; 18(2):428-32. PubMed ID: 22161774
    [No Abstract]   [Full Text] [Related]  

  • 15. Heparin: from animal organ extract to designer drug.
    Middeldorp S
    Thromb Res; 2008; 122(6):753-62. PubMed ID: 17996279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis.
    Money SR; York JW
    Cardiovasc Surg; 2001 Jun; 9(3):211-8. PubMed ID: 11336843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bridging: Perioperative management of chronic anticoagulation or antiplatelet therapy].
    Nowak-Göttl U; Langer F; Limperger V; Mesters R; Trappe RU
    Dtsch Med Wochenschr; 2014 Jun; 139(24):1301-6. PubMed ID: 24892468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Is there a difference between low-molecular-weight heparins?].
    Eritsland J
    Tidsskr Nor Laegeforen; 2005 Oct; 125(20):2802-3. PubMed ID: 16244685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
    Stevenson JL; Choi SH; Varki A
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7003-11. PubMed ID: 16203794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
    Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
    Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.